EAY191-N4 ComboMATCH (Ovarian and Endometrial Cancers) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to compare the outcomes for women who use selumetinib alone and women who use selumetinib plus olaparib to treat endometrial or ovarian cancer. We want to know which option is better for women whose tumors harbor a mutation in a key survival pathway called KRAS.

¿Cuál es la Condición que se está estudiando?

Ovarian or Endometrial Cancer

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with ovarian, primary peritoneal, fallopian tube, or endometrial cancer
Have documented RAS pathway mutations
Are able to have a safe biopsy of their tumor(s) performed or have a biopsy that was done in the last 12 months that confirms tumor mutations
Have disease that has returned after treatment or is not responding to treatment

For more information about this study, please contact the study team at nick.jeffries@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

Si decide unirse a este estudio, se le asignará al azar (como si se lanzara una moneda al aire) a 1 de 2 grupos:

Group 1 will get a regimen of selumetinib and olaparib
Group 2 will get a regimen of selumetinib alone

Detalles del Estudio

Título Completo

EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib alone in Patients with recurrent or persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial

Investigador Principal